CP
LAB icon

Caligan Partners’s Standard BioTools LAB Stock Holding History

Caligan Partners’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,042,413
Closed -$15.6M – 14
2023
Q4 		$15.6M Sell
7,042,413
-580,000
-8% -$1.24M 5.25% 5
2023
Q3 		$22.1M Sell
7,622,413
-845,507
-10% -$2.21M 10.15% 4
2023
Q2 		$16.3M Sell
8,467,920
-108,879
-1% -$215K 9.19% 4
2023
Q1 		$16.7M Hold
8,576,799
– – 11.67% 3
2022
Q4 		$10M Buy
+8,576,799
New +$10.6M 8.35% 5

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Caligan Partners's LAB Position: Q1 2024 in Review

Caligan Partners sold out of Standard BioTools (LAB) in Q1 2024, closing a stake of 7,042,413 shares — an estimated $15.6M sold.

Caligan Partners first reported a position in LAB in Q4 2022 and held it in 5 quarters. The position peaked at $22.1M in Q3 2023. 145 funds tracked by Wall St. Rank hold LAB as of Q1 2024.

  • Caligan Partners reported no remaining Standard BioTools position as of Q1 2024 after selling out during the quarter.
  • Caligan Partners sold 7,042,413 Standard BioTools shares in Q1 2024, an estimated $15.6M.
  • Caligan Partners first reported a position in Standard BioTools in Q4 2022 and held it in 5 quarters.
  • Caligan Partners's Standard BioTools position peaked at $22.1M in Q3 2023.
  • 145 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2024.

Based on Caligan Partners's 13F filing for Q1 2024, filed 13 May 2024.